Daicel Corporation (TYO:4202)

Market Cap	370.91B
Revenue (ttm)	580.23B
Net Income (ttm)	42.91B
Shares Out	265.13M
EPS (ttm)	158.91
PE Ratio	8.80
Forward PE	7.01
Dividend	60.00 (4.29%)
Ex-Dividend Date	Sep 29, 2025

Volume	575,600
Average Volume	562,665
Open	1,390.00
Previous Close	1,388.00
Day's Range	1,380.50 - 1,399.00
52-Week Range	1,057.50 - 1,482.00
Beta	0.20
RSI	60.39
Earnings Date	Nov 6, 2025

About Daicel

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photo...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1919
• Employees: 11,178
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4202

Financial Performance

In 2024, Daicel's revenue was 586.53 billion, an increase of 5.10% compared to the previous year's 558.06 billion. Earnings were 49.48 billion, a decrease of -11.38%.